Developer docs
API playgroundTry for free, no card

Search company profiles

Medicalgorithmics

Full company profile

uuid000a129

Namestring
Medicalgorithmics
Legal namestring
Medicalgorithmics S.A.
Company typeenum
Public
Founded yearint
2005
Descriptiontext

Medicalgorithmics S.A. (WSE: MDG) is a Warsaw-based, publicly traded medical technology company founded in 2005 that develops AI-powered cardiac diagnostics for hospitals, independent diagnostic testing facilities (IDTFs), cardiologists, and clinical trial sponsors. Its portfolio combines proprietary ambulatory ECG hardware (PocketECG, Kardiobeat.ai) with the DeepRhythm Platform (DRP), a hardware-agnostic cloud ECG platform whose core engine is DeepRhythmAI (DRAI), an FDA-cleared deep learning algorithm combining CNN and Transformer models trained on a proprietary library of 250+ billion annotated heartbeats. The company has extended its diagnostic surface into coronary imaging via VCAST, an AI-based system that performs non-invasive hemodynamic analysis of CT scans to assess coronary artery stenosis, and offers end-to-end ECG monitoring services for pharmaceutical clinical trials.

The business operates a multi-revenue-stream model: device sales of cardiac monitoring hardware, SaaS/subscription access to the DRP cloud platform, and usage-based fees for ongoing ECG analysis and arrhythmia monitoring services. Pricing is custom and non-public, sold via multi-year enterprise contracts to healthcare institutions. Distribution combines direct sales (legacy US subsidiary Medi-Lynx, sold to React Group in 2024) with channel partners, notably CardioScan (800,000 tests annually across 11 countries) and Umbrella Biomed (exclusive Saudi Arabia distributor for VCAST). Clinical evidence is central to the go-to-market: the DRAI MARTINI study validated 14x better detection of critical arrhythmias versus standard care, and the company holds regulatory clearances across FDA (including the unique QYX code for DRAI), EU MDR, Health Canada, TGA, MHRA, Israeli MoH, India CDSCO, and Swiss CH-REP.

FY2025 revenue was PLN 31 million (~29% YoY growth), with Q1 2025 revenue up 51% YoY and operating cash flow positive by Q4 2025. The company is pivoting from a hardware-led model toward a software/AI-led model after divesting Medi-Lynx, while investing in new growth vectors including the Lund University cardiac function dataset initiative, VCAST commercialization, cardiac surgery robotics entry, and consumer wearable integrations (Samsung spin-off, Accyourate). Largest shareholder is BioFund Capital Management LLC at 13.60%, with ESOP in place since December 2023 and additional capital from a PARP grant (PLN 9.4M, December 2025) supporting ongoing R&D.

Short descriptiontext

Medicalgorithmics is a Warsaw-listed MedTech company that builds FDA-cleared AI algorithms (DeepRhythmAI) and a hardware-agnostic cloud ECG platform (DeepRhythm Platform) for arrhythmia detection and CT-based coronary assessment, serving hospitals, IDTFs, and clinical trial sponsors across 20+ countries.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersWarsaw, Poland
HQ citystring
Warsaw
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI cardiac diagnostics, ECG monitoring platform, arrhythmia detection software, ambulatory cardiac monitoring, cardiovascular CT analysis
Industry5 codes
PRIMARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)
NAICS code3 codes
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
  • Scientific Research and Development Services5417
  • Custom Computer Programming Services541511
SIC code4 codes
  • Electromedical & Electrotherapeutic Apparatus3845
  • Surgical & Medical Instruments & Apparatus3841
  • Services-Medical Laboratories8071
  • Services-Computer Integrated Systems Design7373
Product category
Cardiac Diagnostics Software
GTM motion3 records

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales
TypeHardware Sales
Description

Sale of cardiac monitoring devices and equipment to healthcare providers, hospitals, and diagnostic centers.

medicalgorithmics.com
2SaaS/Software Services
TypeSubscription Recurring
Description

Cloud-based ECG analysis platform subscription services providing AI-powered cardiac diagnostics and monitoring capabilities to healthcare institutions.

medicalgorithmics.com
3Device Monitoring Fees
TypeUsage Based
Description

Ongoing monitoring fees for continuous ECG recording analysis and arrhythmia detection services provided to healthcare providers.

medicalgorithmics.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Pricing details1 tier
1Enterprise healthcare institutions
ModelOtherBilling cadenceMulti-year contract
Notes

Custom pricing based on institutional requirements, monitoring volume, and service level agreements. No public pricing available.

medicalgorithmics.com
GTM typeB2B
B2B
Offering typeSoftware
Software
Brand1 of 5 records shown
1PocketECG
Description

AI-driven ambulatory ECG monitoring device for real-time arrhythmia detection, full disclosure data, and rich diagnostic reports.

medicalgorithmics.com
+4 more records
Core offering1 text field

Medicalgorithmics develops and sells AI-powered cardiac diagnostics solutions built around its DeepRhythm Platform (DRP), a hardware-agnostic cloud ECG analysis platform powered by DeepRhythmAI (DRAI) deep learning algorithms. The company also manufactures ambulatory ECG monitoring hardware (PocketECG, Kardiobeat.ai) and offers VCAST, an AI-based CT-scan analysis system for coronary artery assessment. Its services include clinical trial ECG monitoring and R&D consulting.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 65% reduction in diagnostic time compared to conventional methods
+2 more records
Product overview1 text field

Medicalgorithmics offers a comprehensive cardiac diagnostics portfolio combining hardware devices and AI-powered cloud software. The core offering centers on DeepRhythm Platform (DRP), a hardware-agnostic cloud ECG platform that processes data from multiple monitoring devices. DRP is powered by DeepRhythmAI (DRAI), FDA-cleared AI algorithms using CNNs and Transformer models for arrhythmia detection. The company manufactures two ambulatory ECG monitoring devices: PocketECG (portable online ECG monitor for up to 30-day monitoring) and Kardiobeat.ai (wireless Holter monitor for 24-hour to 18-day recording). VCAST provides AI-based CT-scan analysis for coronary artery assessment. Services include clinical trial ECG monitoring and R&D services for algorithm, software, and hardware development. The company operates on both device sales and SaaS subscription models.

Product and service7 records
1DeepRhythm Platform (DRP)
CategoryCloud AI Platform
Description

Hardware-agnostic cloud-based AI platform for detecting, classifying, analyzing, and reporting ECG data. Powers arrhythmia diagnosis workflow with automated processes, remote monitoring, and scalable deployment for healthcare institutions.

2DeepRhythmAI (DRAI)
CategoryAI Algorithms / Software
Description

FDA-cleared set of AI algorithms leveraging CNNs and Transformer models to detect and classify arrhythmias in ECG data. Integrates with third-party ECG analysis software and devices, processing Holter, Extended Holter, Event Monitoring, and Mobile Cardiac Telemetry data.

3PocketECG
CategoryMedical Device
Description

Portable, AI-driven online ECG monitoring device for Long-Term Holter, Cardiac Event, and Mobile Cardiac Telemetry analysis. Captures and transmits every heartbeat over monitoring periods up to 30 days with real-time data transmission and comprehensive arrhythmia reporting.

4Kardiobeat.ai
CategoryMedical Device
Description

Lightweight wireless Holter monitor that records continuous ECG for 24 hours up to 18 days. Combines cable-free design with waterproof IP54 rating and AI-powered analysis for comprehensive arrhythmia detection.

5Virtual Cardiac Stress Test (VCAST)
CategoryAI Diagnostic Software
Description

Patented AI-based medical system for non-invasive clinical analysis of CT-scan data to assess hemodynamic significance of coronary artery atherosclerotic stenosis. Provides 3D visualization of coronary anatomy and flow dynamics as alternative to traditional FFR diagnostics.

6Clinical Trials ECG Monitoring
CategoryClinical Trial Service
Description

End-to-end ECG monitoring services for clinical trials supporting sponsors, CROs, and principal investigators. Includes vendor audit documentation, site training, PocketECG deployment, 24/7 monitoring, PI alerts, and final diagnostic reporting for cardiac safety assessment.

7R&D Services
CategoryResearch and Development Services
Description

Research and development services including algorithm development for physiological signal analysis, clinical study design and execution, software development, consulting services, and medical hardware development from concept to prototyping to manufacturing.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership8 partners
1Samsung spin-off company
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2025-11-01
Description

Integration partnership with a Samsung spin-off company for cardiac monitoring technology. The partnership involves embedding or integrating Medicalgorithmics' ECG analysis capabilities into consumer health technology products.

medicalgorithmics.com
2Umbrella Biomed
Strategic tierRegionalTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-01
Description

Distribution partnership for VCAST technology in Saudi Arabia. Umbrella Biomed serves as the exclusive distributor for Medicalgorithmics' VCAST AI system in the Saudi Arabian market, supporting regional healthcare institutions.

medicalgorithmics.com
3CardioScan
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-06-26
Description

Supply agreement with CardioScan, a global leader in cardiac diagnostics. CardioScan processes 800,000 tests annually across 11 countries. The partnership enables Medicalgorithmics to scale its AI-powered ECG analysis globally through CardioScan's established diagnostic network.

medicalgorithmics.com
Strategic tierCoreTypeOthers
Description

Simbec-Orion serves as a clinical trial sponsor utilizing Medicalgorithmics' cardiac monitoring technology for cardiovascular drug development studies. The partnership involves providing ECG monitoring services during clinical investigations.

5Anacardio
Strategic tierCoreTypeOthers
Description

Anacardio is a clinical trial sponsor conducting cardiovascular studies that leverage Medicalgorithmics' AI-powered cardiac monitoring capabilities for patient safety monitoring and endpoint adjudication.

medicalgorithmics.com
Strategic tierCoreTypeOthers
Description

Molecure is a clinical trial sponsor for cardiac drug development programs utilizing Medicalgorithmics' VCAST and ECG monitoring technologies for cardiac safety assessment during clinical trials.

Strategic tierStrategicTypeTechnology or Integration
Description

Technology partnership with Accyourate, an Italian wearable healthcare company. The partnership involves integrating Medicalgorithmics' AI cardiac diagnostics with Accyourate's wearable health monitoring devices for comprehensive consumer health solutions.

Strategic tierRegionalTypeStrategic or Co-development Partner
Description

Collaboration with American Heart of Poland for VCAST clinical study. The partnership involves conducting clinical validation research for VCAST AI technology in partnership with a leading Polish cardiovascular healthcare institution.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Heartbeat Health provides virtual cardiology services including remote cardiac monitoring and arrhythmia management, partially overlapping with Medicalgorithmics' clinical-trials ECG monitoring service and clinical decision support offerings. Smaller scale and primarily US-focused.

TypeEmerging player
Description

CardioSignal develops smartphone-based PPG and ECG-derived algorithms for detecting cardiac conditions including atrial fibrillation, comparable in approach to Medicalgorithmics' consumer/ambulatory AI ECG strategy. Smaller scale, focused on consumer and remote screening use cases.

TypeEmerging player
Description

AliveCor's KardiaMobile is an FDA-cleared AI-enabled consumer ECG device with FDA-cleared algorithms for arrhythmia detection, overlapping with DRAI's algorithmic detection capabilities. Comparable in target use cases (consumer, ambulatory, clinician-facing) though focused on a personal/point-of-care niche rather than enterprise IDTFs.

TypeBroad incumbent
Description

GE HealthCare's cardiology portfolio includes ECG, MUSE cardiac information systems, and AI cardiac imaging tools that compete with both Medicalgorithmics' DRP platform and VCAST in hospital cardiology departments. Operates broadly across cardiac care rather than specializing in ambulatory AI ECG.

TypeDirect peer
Description

iRhythm's Zio long-term ambulatory ECG monitor with AI arrhythmia classification is the closest direct comparison to Medicalgorithmics' PocketECG and DRAI platform. Both companies target the same cardiology channel (IDTFs, cardiologists, hospitals) with AI-augmented ECG monitoring and compete for share of the same clinical workflow.

TypeBroad incumbent
Description

Philips offers a broad portfolio of cardiac monitoring, ECG, and AI-enabled cardiology solutions including IntelliVue and the previously acquired BioTelemetry ambulatory monitoring business. Overlaps with Medicalgorithmics across ambulatory ECG, telemetry, and AI cardiac analysis, but as part of a much larger diversified medtech portfolio.

TypeDirect peer
Description

HeartFlow's CT-FFR (fractional flow reserve derived from coronary CT) is the leading non-invasive alternative to invasive catheter-based FFR, directly comparable to Medicalgorithmics' VCAST Virtual Cardiac Stress Test. Both target the same cardiology and radiology buyers evaluating coronary stenosis without catheterization.

8Biofourmis
TypeEmerging player
Description

Biofourmis provides AI-based remote patient monitoring and virtual care platforms including cardiac RPM, comparable in technology stack and care delivery model to Medicalgorithmics' DRP cloud platform. Targets similar enterprise health system and payer customers with a broader chronic condition portfolio.

TypeBroad incumbent
Description

Boston Scientific acquired Preventice Solutions, a major ambulatory cardiac monitoring (BodyGuardian) provider, giving it enterprise cardiac monitoring reach comparable to Medicalgorithmics' PocketECG/DRAI offering. Competes across the IDTF and hospital ambulatory cardiology channels with a broader device portfolio.

TypeEmerging player
Description

Eko combines digital stethoscopes and ECG with FDA-cleared AI algorithms for cardiac murmur and arrhythmia detection, comparable to Medicalgorithmics' DRAI suite. Targets overlapping clinician segments (primary care, cardiology) with embedded AI analysis.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
Yes

Docs URL, Description

Integration4 records

Each record includes

Title, Type, Description, Source

AI capability10 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles14 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance12 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Medicalgorithmics

Cardiac Diagnostics Softwaremedicalgorithmics.com

Medicalgorithmics is a Warsaw-listed MedTech company that builds FDA-cleared AI algorithms (DeepRhythmAI) and a hardware-agnostic cloud ECG platform (DeepRhythm Platform) for arrhythmia detection and CT-based coronary assessment, serving hospitals, IDTFs, and clinical trial sponsors across 20+ countries.

What Medicalgorithmics does

Medicalgorithmics S.A. (WSE: MDG) is a Warsaw-based, publicly traded medical technology company founded in 2005 that develops AI-powered cardiac diagnostics for hospitals, independent diagnostic testing facilities (IDTFs), cardiologists, and clinical trial sponsors. Its portfolio combines proprietary ambulatory ECG hardware (PocketECG, Kardiobeat.ai) with the DeepRhythm Platform (DRP), a hardware-agnostic cloud ECG platform whose core engine is DeepRhythmAI (DRAI), an FDA-cleared deep learning algorithm combining CNN and Transformer models trained on a proprietary library of 250+ billion annotated heartbeats. The company has extended its diagnostic surface into coronary imaging via VCAST, an AI-based system that performs non-invasive hemodynamic analysis of CT scans to assess coronary artery stenosis, and offers end-to-end ECG monitoring services for pharmaceutical clinical trials.

The business operates a multi-revenue-stream model: device sales of cardiac monitoring hardware, SaaS/subscription access to the DRP cloud platform, and usage-based fees for ongoing ECG analysis and arrhythmia monitoring services. Pricing is custom and non-public, sold via multi-year enterprise contracts to healthcare institutions. Distribution combines direct sales (legacy US subsidiary Medi-Lynx, sold to React Group in 2024) with channel partners, notably CardioScan (800,000 tests annually across 11 countries) and Umbrella Biomed (exclusive Saudi Arabia distributor for VCAST). Clinical evidence is central to the go-to-market: the DRAI MARTINI study validated 14x better detection of critical arrhythmias versus standard care, and the company holds regulatory clearances across FDA (including the unique QYX code for DRAI), EU MDR, Health Canada, TGA, MHRA, Israeli MoH, India CDSCO, and Swiss CH-REP.

FY2025 revenue was PLN 31 million (~29% YoY growth), with Q1 2025 revenue up 51% YoY and operating cash flow positive by Q4 2025. The company is pivoting from a hardware-led model toward a software/AI-led model after divesting Medi-Lynx, while investing in new growth vectors including the Lund University cardiac function dataset initiative, VCAST commercialization, cardiac surgery robotics entry, and consumer wearable integrations (Samsung spin-off, Accyourate). Largest shareholder is BioFund Capital Management LLC at 13.60%, with ESOP in place since December 2023 and additional capital from a PARP grant (PLN 9.4M, December 2025) supporting ongoing R&D.

Medicalgorithmics firmographics

Firmographics
Name
Medicalgorithmics
Legal name
Medicalgorithmics S.A.
Website
https://medicalgorithmics.com
Company type
Public
Founded year
2005
Operating status
Operating
Headcount range
101–250 employees
Short description
Medicalgorithmics is a Warsaw-listed MedTech company that builds FDA-cleared AI algorithms (DeepRhythmAI) and a hardware-agnostic cloud ECG platform (DeepRhythm Platform) for arrhythmia detection and CT-based coronary assessment, serving hospitals, IDTFs, and clinical trial sponsors across 20+ countries.
Ownership category
akta.pro rank

Medicalgorithmics industry classification

Industry
Product category
Cardiac Diagnostics Software
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Scientific Research and Development Services (5417), Custom Computer Programming Services (541511)
SIC
Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071), Services-Computer Integrated Systems Design (7373)
akta.pro industry
PRIMARYHLALAGAB
Cardiology Telemedicine Platforms
Healthcare & Life Sciences/Telehealth Platforms/Specialty Telemedicine Platforms (e.g., dermatology, cardiology, neurology)
SECONDARYHLACAFAM
AI/Analytics for RPM (Risk Stratification, Alerts, Predictive)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHLACAFAG
Medical-Grade Device Connectivity & Device Management (MDM)
Healthcare & Life Sciences/Digital Health & Health IT/Remote Patient Monitoring (RPM) & Connected Care Platforms
SECONDARYHDAAAEAH
Medical Imaging AI
SECONDARYHLAHAFAI
Hemodynamic Monitoring & Cardiac Diagnostics (Cath Lab, FFR/IVUS/OCT)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Cardiovascular Devices (Stents, Valves, Rhythm Management)

Keywords

  • AI cardiac diagnostics
  • ECG monitoring platform
  • Arrhythmia detection software
  • Ambulatory cardiac monitoring
  • Cardiovascular CT analysis

Where Medicalgorithmics is headquartered

Location

Headquarters

HQ city
Warsaw
HQ country
Poland
HQ region
Europe

Offices2 records

Markets served

Medicalgorithmics business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales: Sale of cardiac monitoring devices and equipment to healthcare providers, hospitals, and diagnostic centers.
  2. SaaS/Software Services: Cloud-based ECG analysis platform subscription services providing AI-powered cardiac diagnostics and monitoring capabilities to healthcare institutions.
  3. Device Monitoring Fees: Ongoing monitoring fees for continuous ECG recording analysis and arrhythmia detection services provided to healthcare providers.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractEnterprise healthcare institutions

Go-to-market motion3 records

Distribution channels4 records

Marketing channels3 records

Medicalgorithmics product offering

Product offering

Core offering

Medicalgorithmics develops and sells AI-powered cardiac diagnostics solutions built around its DeepRhythm Platform (DRP), a hardware-agnostic cloud ECG analysis platform powered by DeepRhythmAI (DRAI) deep learning algorithms. The company also manufactures ambulatory ECG monitoring hardware (PocketECG, Kardiobeat.ai) and offers VCAST, an AI-based CT-scan analysis system for coronary artery assessment. Its services include clinical trial ECG monitoring and R&D consulting.

Product overview

Medicalgorithmics offers a comprehensive cardiac diagnostics portfolio combining hardware devices and AI-powered cloud software. The core offering centers on DeepRhythm Platform (DRP), a hardware-agnostic cloud ECG platform that processes data from multiple monitoring devices. DRP is powered by DeepRhythmAI (DRAI), FDA-cleared AI algorithms using CNNs and Transformer models for arrhythmia detection. The company manufactures two ambulatory ECG monitoring devices: PocketECG (portable online ECG monitor for up to 30-day monitoring) and Kardiobeat.ai (wireless Holter monitor for 24-hour to 18-day recording). VCAST provides AI-based CT-scan analysis for coronary artery assessment. Services include clinical trial ECG monitoring and R&D services for algorithm, software, and hardware development. The company operates on both device sales and SaaS subscription models.

Differentiator

Problem solved

Functional benefit

Brands

  • PocketECG: AI-driven ambulatory ECG monitoring device for real-time arrhythmia detection, full disclosure data, and rich diagnostic reports.
  • Kardiobeat.ai
  • DeepRhythmAI (DRAI)
  • DeepRhythm Platform (DRP)
  • VCAST

Products and services

  • DeepRhythm Platform (DRP) Hardware-agnostic cloud-based AI platform for detecting, classifying, analyzing, and reporting ECG data. Powers arrhythmia diagnosis workflow with automated processes, remote monitoring, and scalable deployment for healthcare institutions.
  • DeepRhythmAI (DRAI) FDA-cleared set of AI algorithms leveraging CNNs and Transformer models to detect and classify arrhythmias in ECG data. Integrates with third-party ECG analysis software and devices, processing Holter, Extended Holter, Event Monitoring, and Mobile Cardiac Telemetry data.
  • PocketECG Portable, AI-driven online ECG monitoring device for Long-Term Holter, Cardiac Event, and Mobile Cardiac Telemetry analysis. Captures and transmits every heartbeat over monitoring periods up to 30 days with real-time data transmission and comprehensive arrhythmia reporting.
  • Kardiobeat.ai Lightweight wireless Holter monitor that records continuous ECG for 24 hours up to 18 days. Combines cable-free design with waterproof IP54 rating and AI-powered analysis for comprehensive arrhythmia detection.
  • Virtual Cardiac Stress Test (VCAST) Patented AI-based medical system for non-invasive clinical analysis of CT-scan data to assess hemodynamic significance of coronary artery atherosclerotic stenosis. Provides 3D visualization of coronary anatomy and flow dynamics as alternative to traditional FFR diagnostics.
  • Clinical Trials ECG Monitoring End-to-end ECG monitoring services for clinical trials supporting sponsors, CROs, and principal investigators. Includes vendor audit documentation, site training, PocketECG deployment, 24/7 monitoring, PI alerts, and final diagnostic reporting for cardiac safety assessment.
  • R&D Services Research and development services including algorithm development for physiological signal analysis, clinical study design and execution, software development, consulting services, and medical hardware development from concept to prototyping to manufacturing.

Quantifiable outcome

  • 65% reduction in diagnostic time compared to conventional methods
  • +2 more outcomes

Companies that use Medicalgorithmics

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles4 records

Medicalgorithmics technology and API

Technology

Technology focussed Yes

API detail

Has API
Yes
API docs
API detail

Core technology

AI maturity

App detail

Integration4 records

AI capability10 records

Feature5 records

Medicalgorithmics partnerships and signals

Strategic signal

Partnerships

Eight partnerships are on record, tiered strategic, regional and core.

  • Samsung spin-off companystrategicTechnology or Integration · 1 November 2025Integration partnership with a Samsung spin-off company for cardiac monitoring technology. The partnership involves embedding or integrating Medicalgorithmics' ECG analysis capabilities into consumer health technology products.
  • Umbrella BiomedregionalChannel Partner/ Reseller/ Distributor · 1 October 2025Distribution partnership for VCAST technology in Saudi Arabia. Umbrella Biomed serves as the exclusive distributor for Medicalgorithmics' VCAST AI system in the Saudi Arabian market, supporting regional healthcare institutions.
  • CardioScancoreChannel Partner/ Reseller/ Distributor · 26 June 2025Supply agreement with CardioScan, a global leader in cardiac diagnostics. CardioScan processes 800,000 tests annually across 11 countries. The partnership enables Medicalgorithmics to scale its AI-powered ECG analysis globally through CardioScan's established diagnostic network.
  • Simbec-OrioncoreOthersSimbec-Orion serves as a clinical trial sponsor utilizing Medicalgorithmics' cardiac monitoring technology for cardiovascular drug development studies. The partnership involves providing ECG monitoring services during clinical investigations.
  • AnacardiocoreOthersAnacardio is a clinical trial sponsor conducting cardiovascular studies that leverage Medicalgorithmics' AI-powered cardiac monitoring capabilities for patient safety monitoring and endpoint adjudication.
  • MolecurecoreOthersMolecure is a clinical trial sponsor for cardiac drug development programs utilizing Medicalgorithmics' VCAST and ECG monitoring technologies for cardiac safety assessment during clinical trials.
  • AccyouratestrategicTechnology or IntegrationTechnology partnership with Accyourate, an Italian wearable healthcare company. The partnership involves integrating Medicalgorithmics' AI cardiac diagnostics with Accyourate's wearable health monitoring devices for comprehensive consumer health solutions.
  • American Heart of PolandregionalStrategic or Co-development PartnerCollaboration with American Heart of Poland for VCAST clinical study. The partnership involves conducting clinical validation research for VCAST AI technology in partnership with a leading Polish cardiovascular healthcare institution.

Scale indicators8 records

Recent moves7 records

Expansion highlights7 records

Medicalgorithmics competitors and assessment

Company assessment

Emerging players

  • Heartbeat Health: Heartbeat Health provides virtual cardiology services including remote cardiac monitoring and arrhythmia management, partially overlapping with Medicalgorithmics' clinical-trials ECG monitoring service and clinical decision support offerings. Smaller scale and primarily US-focused.
  • CardioSignal: CardioSignal develops smartphone-based PPG and ECG-derived algorithms for detecting cardiac conditions including atrial fibrillation, comparable in approach to Medicalgorithmics' consumer/ambulatory AI ECG strategy. Smaller scale, focused on consumer and remote screening use cases.
  • AliveCor: AliveCor's KardiaMobile is an FDA-cleared AI-enabled consumer ECG device with FDA-cleared algorithms for arrhythmia detection, overlapping with DRAI's algorithmic detection capabilities. Comparable in target use cases (consumer, ambulatory, clinician-facing) though focused on a personal/point-of-care niche rather than enterprise IDTFs.
  • Biofourmis: Biofourmis provides AI-based remote patient monitoring and virtual care platforms including cardiac RPM, comparable in technology stack and care delivery model to Medicalgorithmics' DRP cloud platform. Targets similar enterprise health system and payer customers with a broader chronic condition portfolio.
  • Eko Health: Eko combines digital stethoscopes and ECG with FDA-cleared AI algorithms for cardiac murmur and arrhythmia detection, comparable to Medicalgorithmics' DRAI suite. Targets overlapping clinician segments (primary care, cardiology) with embedded AI analysis.

Broad incumbents

  • GE HealthCare (Cardiac Diagnostics): GE HealthCare's cardiology portfolio includes ECG, MUSE cardiac information systems, and AI cardiac imaging tools that compete with both Medicalgorithmics' DRP platform and VCAST in hospital cardiology departments. Operates broadly across cardiac care rather than specializing in ambulatory AI ECG.
  • Philips (Cardiac Monitoring): Philips offers a broad portfolio of cardiac monitoring, ECG, and AI-enabled cardiology solutions including IntelliVue and the previously acquired BioTelemetry ambulatory monitoring business. Overlaps with Medicalgorithmics across ambulatory ECG, telemetry, and AI cardiac analysis, but as part of a much larger diversified medtech portfolio.
  • Boston Scientific: Boston Scientific acquired Preventice Solutions, a major ambulatory cardiac monitoring (BodyGuardian) provider, giving it enterprise cardiac monitoring reach comparable to Medicalgorithmics' PocketECG/DRAI offering. Competes across the IDTF and hospital ambulatory cardiology channels with a broader device portfolio.

Direct peers

  • iRhythm Technologies: iRhythm's Zio long-term ambulatory ECG monitor with AI arrhythmia classification is the closest direct comparison to Medicalgorithmics' PocketECG and DRAI platform. Both companies target the same cardiology channel (IDTFs, cardiologists, hospitals) with AI-augmented ECG monitoring and compete for share of the same clinical workflow.
  • HeartFlow: HeartFlow's CT-FFR (fractional flow reserve derived from coronary CT) is the leading non-invasive alternative to invasive catheter-based FFR, directly comparable to Medicalgorithmics' VCAST Virtual Cardiac Stress Test. Both target the same cardiology and radiology buyers evaluating coronary stenosis without catheterization.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Medicalgorithmics social profiles

Digital presence

Medicalgorithmics compliance and trust

Trust signal

Compliance12 records

Medicalgorithmics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Medicalgorithmics leadership team

Management profile

Number of profiles

Profiles14 records

Medicalgorithmics subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Medicalgorithmics funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Medicalgorithmics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Medicalgorithmics

What does Medicalgorithmics do?

Medicalgorithmics develops and sells AI-powered cardiac diagnostics solutions built around its DeepRhythm Platform (DRP), a hardware-agnostic cloud ECG analysis platform powered by DeepRhythmAI (DRAI) deep learning algorithms. The company also manufactures ambulatory ECG monitoring hardware (PocketECG, Kardiobeat.ai) and offers VCAST, an AI-based CT-scan analysis system for coronary artery assessment. Its services include clinical trial ECG monitoring and R&D consulting.

Is Medicalgorithmics a public or private company?

Medicalgorithmics is a public company. It is classified as public and is currently operating.

When was Medicalgorithmics founded?

Medicalgorithmics was founded in 2005. It employs 101 to 250 people.

Where is Medicalgorithmics based?

Medicalgorithmics is headquartered in Warsaw, Poland, in the Europe region.

How does Medicalgorithmics make money?

Three revenue lines are on record. Medical Device Sales are the primary driver. The others are saaS/Software Services and device Monitoring Fees.

Who are Medicalgorithmics's main competitors?

Emerging players on record are Heartbeat Health, CardioSignal, AliveCor, Biofourmis and Eko Health. Broad incumbents are GE HealthCare (Cardiac Diagnostics), Philips (Cardiac Monitoring) and Boston Scientific. Direct peers are iRhythm Technologies and HeartFlow.

Does Medicalgorithmics have an API?

Yes. DRP offers a robust API for seamless integration with existing medical devices and EMR systems, minimizing disruption to workflow. DRAI is designed as an API-integrated AI solution intended for integration with third-party ECG analysis software and devices.

What industry is Medicalgorithmics in?

Medicalgorithmics's product category is Cardiac Diagnostics Software. Its primary akta.pro industry code is HLALAGAB, Cardiology Telemedicine Platforms, with a secondary code of HLACAFAM, AI/Analytics for RPM (Risk Stratification, Alerts, Predictive). Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingMedicalgorithmics Proposes Share Capital Increase Via Two Emissions Of R and S Series SharesMedicalgorithmics SA proposed a share capital increase via emissions of up to 1.05 million Series R shares and up to 1.00 million Series S shares. The Series R issuance is expected to raise PLN 20.9 million, and the Series S issuance at least PLN 33.0 million, with proceeds for operations, development, foreign expansion, and working capital.MamStartupMedicalgorithmics na progu przejęcia przez amerykańską spółkę z Nasdaq. Transakcja warta co najmniej 67 mln dolarówA Nasdaq-listed healthcare company signed a letter of intent to acquire all shares of Medicalgorithmics for at least $67 million. The deal would be paid in common stock, with the new shares representing up to 49% of voting rights. Medicalgorithmics must raise at least €10 million in non-debt financing before the final agreement.Investing.comWhy is Medicalgorithmics stock surging today?Medicalgorithmics stock surged 6.4% to 26.75 PLN after signing a Letter of Intent with a Nasdaq-listed healthcare firm for a potential 100% acquisition at $67 million. The deal requires the company to raise €10 million in equity, and Q3 2026 revenue rose 52% year-over-year. Analysts rate the stock a Strong Buy with a 40.85 PLN price target.The future of tradingPoland's Medicalgorithmics Signs LOI For Potential $67 Mln Takeover By US Nasdaq-Listed FirmPoland's Medicalgorithmics signed a letter of intent for a potential 100% takeover by a US healthcare company listed on NASDAQ. The total consideration is valued at not less than $67 million, to be settled primarily in the investor's common shares, with non-debt equity financing of at least EUR 10 million to be obtained before or at signing of the final agreement.MedicalgorithmicsMedicalgorithmics enters supply agreement with CardioScan, a global leader in cardiac diagnostics – 800,000 tests annually in 11 countriesMedicalgorithmics has entered a supply agreement with CardioScan, a global leader in cardiac diagnostics, for 800,000 tests annually across 11 countries.Mpo-magFDA Approves Medicalgorithmics' Qpatch ECG WearableThe FDA approved Medicalgorithmics' Qpatch ECG wearable, which measures individual ECG signals for cardiac arrhythmia diagnosis. The device can monitor for up to 15 days and includes an eInk screen and real-time ECG reading via smartphone. The company plans to prepare for U.S. market entry and pursue foreign markets.PR NewswireMEDICALGORITHMICS secured FDA approval for Qpatch wearableThe US Food and Drug Administration granted approval for Qpatch, an ECG wearable device developed by Medicalgorithmics, enabling its use in the United States. This regulatory clearance allows Medicalgorithmics to proceed with market entry for the 15-day cardiac monitoring solution in the US and potentially other foreign regions.LifescienceMedTech, czyli technologia w służbie medycynyThe MedTech industry is growing rapidly, with the market projected to exceed $420 billion in 2018. In 2016, over 12,000 patent applications were filed, and telemedicine is the fastest-growing segment. Polish startups like Medicalgorythmics and Braster are gaining international recognition.PR NewswireNew Research Demonstrates Online ECG Monitoring is More Effective than Offline Holter and Patch Methods to Detect Paroxysmal ArrhythmiaMedicalgorithmics, S.A. presented study results at the 2018 Heart Rhythm Society Annual Scientific Sessions indicating that its PocketECG online monitoring system significantly outperforms traditional offline Holter and patch methods in detecting paroxysmal atrial fibrillation. The analysis of 16,595 cardiac telemetry reports showed that online monitoring yielded diagnostic rates up to six times higher than 24-hour Holter monitoring for low-burden arrhythmias.PR NewswireNew Study Examines Online Vs Offline ECG Monitoring to Detect Difficult-to-Diagnose ArrhythmiaMEDICALgorithmics S.A. announced that a study comparing online versus offline ECG monitoring for detecting paroxysmal atrial fibrillation will be presented at the Heart Rhythm Society conference on May 10 by lead author Marek Dziubiński, PhD, inventor of the PocketECG system. The study examines diagnostic yield differences based on monitoring duration in patients with the arrhythmia condition. MEDICALgorithmics, a Polish cardiac monitoring company listed on the Warsaw Stock Exchange, also highlighted its PocketECG device and US subsidiary Medi-Lynx Cardiac Monitoring in the announcement.